Literature DB >> 22079237

Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction.

Melissa J Alldred1, Karen E Duff, Stephen D Ginsberg.   

Abstract

The hTau mouse model of tauopathy was utilized to assess gene expression changes in vulnerable hippocampal CA1 neurons. CA1 pyramidal neurons were microaspirated via laser capture microdissection followed by RNA amplification in combination with custom-designed microarray analysis and qPCR validation in hTau mice and nontransgenic (ntg) littermates aged 11-14months. Statistical analysis revealed ~8% of all the genes on the array platform were dysregulated, with notable downregulation of several synaptic-related markers including synaptophysin (Syp), synaptojanin, and synaptobrevin, among others. Downregulation was also observed for select glutamate receptors (GluRs), Psd-95, TrkB, and several protein phosphatase subunits. In contrast, upregulation of tau isoforms and a calpain subunit were found. Microarray assessment of synaptic-related markers in a separate cohort of hTau mice at 7-8months of age indicated only a few alterations compared to the 11-14month cohort, suggesting progressive synaptic dysfunction occurs as tau accumulates in CA1 pyramidal neurons. An assessment of SYP and PSD-95 expression was performed in the hippocampal CA1 sector of hTau and ntg mice via confocal laser scanning microscopy along with hippocampal immunoblot analysis for protein-based validation of selected microarray observations. Results indicate significant decreases in SYP-immunoreactive and PSD-95-immunoreactive puncta as well as downregulation of SYP-immunoreactive and PSD-95-immunoreactive band intensity in hTau mice compared to age-matched ntg littermates. In summary, the high prevalence of downregulation of synaptic-related genes indicates that the moderately aged hTau mouse may be a model of tau-induced synaptodegeneration, and has profound effects on how we perceive progressive tau pathology affecting synaptic transmission in AD.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079237      PMCID: PMC3259262          DOI: 10.1016/j.nbd.2011.10.022

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  78 in total

Review 1.  mRna expression analysis of tissue sections and single cells.

Authors:  J Eberwine; J E Kacharmina; C Andrews; K Miyashiro; T McIntosh; K Becker; T Barrett; D Hinkle; G Dent; P Marciano
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

2.  Transcriptional profiling of small samples in the central nervous system.

Authors:  Stephen D Ginsberg
Journal:  Methods Mol Biol       Date:  2008

3.  Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau.

Authors:  Dara L Dickstein; Hannah Brautigam; Steven D Stockton; James Schmeidler; Patrick R Hof
Journal:  Brain Struct Funct       Date:  2010-03-07       Impact factor: 3.270

4.  The use of real-time PCR analysis in a gene expression study of Alzheimer's disease post-mortem brains.

Authors:  Ramana V Gutala; P Hemachandra Reddy
Journal:  J Neurosci Methods       Date:  2004-01-15       Impact factor: 2.390

Review 5.  The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors.

Authors:  Stephen D Skaper
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-02       Impact factor: 4.388

6.  AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of non-demented elderly and patients with Alzheimer's disease.

Authors:  D M Armstrong; M D Ikonomovic; R Sheffield; R J Wenthold
Journal:  Brain Res       Date:  1994-03-14       Impact factor: 3.252

7.  Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules.

Authors:  Daniela Fischer; Marco D Mukrasch; Jacek Biernat; Stefan Bibow; Martin Blackledge; Christian Griesinger; Eckhard Mandelkow; Markus Zweckstetter
Journal:  Biochemistry       Date:  2009-10-27       Impact factor: 3.162

8.  Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology.

Authors:  Manuela Polydoro; Christopher M Acker; Karen Duff; Pablo E Castillo; Peter Davies
Journal:  J Neurosci       Date:  2009-08-26       Impact factor: 6.167

9.  The AMPA glutamate receptor GluR3 is enriched in oxytocinergic magnocellular neurons and is localized at synapses.

Authors:  S D Ginsberg; D L Price; C D Blackstone; R L Huganir; L J Martin
Journal:  Neuroscience       Date:  1995-03       Impact factor: 3.590

Review 10.  Functional genomic methodologies.

Authors:  Stephen D Ginsberg; Károly Mirnics
Journal:  Prog Brain Res       Date:  2006       Impact factor: 2.453

View more
  38 in total

1.  Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology.

Authors:  Stephen D Ginsberg; Michael H Malek-Ahmadi; Melissa J Alldred; Yinghua Chen; Kewei Chen; Moses V Chao; Scott E Counts; Elliott J Mufson
Journal:  Neurobiol Dis       Date:  2019-07-23       Impact factor: 5.996

2.  Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimer's Disease.

Authors:  Anna Antonell; Albert Lladó; Raquel Sánchez-Valle; Coral Sanfeliu; Teresa Casserras; Lorena Rami; Cristina Muñoz-García; Adrià Dangla-Valls; Mircea Balasa; Patricia Boya; Susana G Kalko; José Luis Molinuevo
Journal:  Mol Neurobiol       Date:  2015-10-28       Impact factor: 5.590

3.  Expression profiling suggests microglial impairment in human immunodeficiency virus neuropathogenesis.

Authors:  Stephen D Ginsberg; Melissa J Alldred; Satya M Gunnam; Consuelo Schiroli; Sang Han Lee; Susan Morgello; Tracy Fischer
Journal:  Ann Neurol       Date:  2018-02-10       Impact factor: 10.422

4.  Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment.

Authors:  Scott E Counts; Melissa J Alldred; Shaoli Che; Stephen D Ginsberg; Elliott J Mufson
Journal:  Neuropharmacology       Date:  2013-10-25       Impact factor: 5.250

5.  Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  FASEB J       Date:  2019-06-10       Impact factor: 5.191

Review 6.  Tau Proteins and Tauopathies in Alzheimer's Disease.

Authors:  Fong Ping Chong; Khuen Yen Ng; Rhun Yian Koh; Soi Moi Chye
Journal:  Cell Mol Neurobiol       Date:  2018-01-03       Impact factor: 5.046

7.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

8.  Maternal choline supplementation programs greater activity of the phosphatidylethanolamine N-methyltransferase (PEMT) pathway in adult Ts65Dn trisomic mice.

Authors:  Jian Yan; Stephen D Ginsberg; Brian Powers; Melissa J Alldred; Arthur Saltzman; Barbara J Strupp; Marie A Caudill
Journal:  FASEB J       Date:  2014-06-24       Impact factor: 5.191

9.  Synaptic alterations in the rTg4510 mouse model of tauopathy.

Authors:  Katherine J Kopeikina; Manuela Polydoro; Hwan-Ching Tai; Erich Yaeger; George A Carlson; Rose Pitstick; Bradley T Hyman; Tara L Spires-Jones
Journal:  J Comp Neurol       Date:  2013-04-15       Impact factor: 3.215

10.  Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD).

Authors:  Melissa J Alldred; Sang Han Lee; Eva Petkova; Stephen D Ginsberg
Journal:  Brain Struct Funct       Date:  2014-07-17       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.